An observational study in Coronary Artery Disease, Percutaneous Coronary Intervention and Dual Antiplatelet Therapy, sponsored by Genoss Co., Ltd.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-02-21.
Sponsored by Genoss Co., Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Coronary Artery Disease by Genoss Co., Ltd. — 6 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Genoss Co., Ltd..
Among the 10 studies in Coronary Artery Disease by Genoss Co., Ltd., this one is one of 2 that started in 2022, is one of 6 observational ones, and was the 6th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →6 of the 10 studies in Coronary Artery Disease by Genoss Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 20+
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 1,000 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 214 across the 4 interventional studies, 1,000 across the 6 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Genoss Co., Ltd. is the lead sponsor of 18 studies on the registry; 11 are open to participants now.
1 of the studies in Coronary Artery Disease by Genoss Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06066450Genoss Co., Ltd.Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Coronary Artery Disease by Genoss Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of study is to evaluate the efficacy and safety of 1 year duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure.
The Genoss DES is a novel, biodegradable, polymer-coated, sirolimus eluting stent with a cobalt-chromium stent platform and thin strut. Although the efficacy and safety of this stent have been previously investigated, real-world clinical outcomes data are lacking. Therefore, the objective of this prospective, multicenter study was to evaluate the clinical efficacy and safety of 1 year duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure.
The Genoss DES registry is a prospective, single-arm, observational study for evaluation of clinical outcomes of 1 year duration of DAPT after Genoss DES implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure from 9 sites in South Korea. The primary endpoint was a deviceoriented composite endpoint (DOCE), defined as a composite of cardiac death, target vessel-related myocardial infarction (MI), and clinically indicated target lesion revascularization (TLR) at 12 months. The key secondary endpoint was a patient-oriented composite endpoint (POCE), defined as a composite of all-cause death, any myocardial infarction, and any revascularization at 12 months.
Patients with coronary artery disease treated with GENOSS DES
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with coronary artery disease treated with the GENOSS DES \<Definition of a complex high-risk patients\> 1. Clinical factors * Age 75 or older * History of diabetes (those who have had diabetes in the past or are taking diabetes medication) * History of chronic kidney disease (GFR \<60ml/min/1.73m2) or dialysis * History of stroke * History of coronary artery bypass graft * Left ventricular dysfunction (LVEF \<40%) * Severe valve disease * Acute coronary syndrome with positive troponin levels 2. Lesion/procedure factors * Left main lesion * Chronic total occlusion * Bifurcation lesion with branches larger than 2 mm * Calcified lesion (moderate to severe calcified lesion) * Restenosis lesion (in-stent restenosis) * Multivessel PCI * Three or more stents implanted (≥3 stents implanted) * When the stent length of one lesion is more than 50 mm (total stent length \>50 mm in a lesion)
Device-oriented composite endpoint
DOCE is defined as a composite of cardiac death, target vessel-related myocardial infarction (TV-MI) and clinically indicated target-lesion revascularization (TLR).
Time frame: at 12 months after the procedure
Patient-oriented composite endpoint
POCE is defined as a composite of all-cause death, any myocardial infarction, and any revascularization.
Time frame: at 12 months after the procedure
All-cause deaths
Time frame: at 12 months after the procedure
Cardiac death
Time frame: at 12 months after the procedure
Non-cardiac death
Time frame: at 12 months after the procedure
Any myocardial infarction
Time frame: at 12 months after the procedure
Target vessel-realted myocardial infarction (TV-MI)
Time frame: at 12 months after the procedure
Any revascularization
Time frame: at 12 months after the procedure
Revascularization of clinically appropriate target lesions
Time frame: at 12 months after the procedure
Stent thrombosis by ARC definition
Time frame: at 12 months after the procedure
Lesion success
When the final residual lesion stenosis is less than 30% using any surgical method.
Time frame: during the procedure
Procedure success
When the final residual lesion stenosis is less than 30% using any surgical method, and there is no post-procedure death, myocardial infarction, or revascularization during the hospitalization period.
Time frame: immediately after the procedure
Plan to share: No — No The data set is available from the the corresponding author upon reasonable request.
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for Dec 2027, 67 months after the start.
Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 67 months is above that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genoss Co., Ltd.